<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002002</url>
  </required_header>
  <id_info>
    <org_study_id>056A</org_study_id>
    <secondary_id>76-9</secondary_id>
    <nct_id>NCT00002002</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lederle Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effectiveness of l-leucovorin in&#xD;
      preventing toxicity from high dose trimethoprim / sulfamethoxazole (TMP / SMX) used as a&#xD;
      therapy for Pneumocystis carinii pneumonia (PCP) in patients with AIDS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Diagnosis of PCP.&#xD;
&#xD;
          -  Fit the CDC definition of AIDS.&#xD;
&#xD;
          -  Be receiving intravenous or oral trimethoprim / sulfamethoxazole (Bactrim, Septra) in&#xD;
             doses of = or &gt; 15mg/kg/day of the trimethoprim component.&#xD;
&#xD;
          -  Be receiving = or &lt; 48 hours of trimethoprim / sulfamethoxazole (TMP / SMX) prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Must sign informed consent in accordance with FDA guidelines.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Cannot take oral medications.&#xD;
&#xD;
          -  Require continued administration of anticonvulsant agents such as phenytoin,&#xD;
             phenobarbital or primidone.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Continued administration of anticonvulsant agents such as phenytoin, phenobarbital or&#xD;
             primidone.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Cannot take oral medications.&#xD;
&#xD;
          -  Require continued administration of anticonvulsant agents such as phenytoin,&#xD;
             phenobarbital or primidone.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  &gt; 48 hours of trimethoprim / sulfamethoxazole prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis. 1994 Oct;170(4):912-7. doi: 10.1093/infdis/170.4.912.</citation>
    <PMID>7930736</PMID>
  </reference>
  <verification_date>July 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

